All these accumulated evidences point to the analyses of serine peptidases such as DPPIV as promising tools in the design of new diagnostic/prognostic biomarkers and therapeutic targets in CRC [14,20–26]. The gene discussed is FAP; the disease is colorectal carcinoma.